GRAIL Stock Tumbles - National Health Service Galleri Trial To Blame
GRAIL Inc. (NASDAQ:GRAL) shares are down during Monday's premarket session following the release of results from the NHS-Galleri trial, which evaluated the effectiveness of the Galleri test in reducing late-stage cancer diagnoses.
NHS-Galleri Trial Results
The NHS-Galleri trial results showed a favorable trend in reducing Stage IV cancer diagnoses, although the primary endpoint was not met. On Friday, GRAIL stock closed almost 51% lower.
The trial evaluated annual multi-cancer screening with the Galleri test in England's National Health Service (NHS) over three years, involving 142,000 participants aged 50 to 77.
The results indicated a clinically meaningful reduction in Stage IV diagnoses across a group of 12 deadly cancers, with a more than 20% reduction observed in subsequent screening rounds.
The broader market experienced declines on the previous trading day, with the Russell 2000 down 0.72% and the S&P 500 falling 0.50%.
GRAIL's decline occurred while the broader market was under pressure, suggesting that the stock's movement is primarily driven by company-specific news rather than overall market trends.
GRAIL's Technical Indicators Highlight Weakness
The stock is currently trading 47.3% below its 20-day simple moving average (SMA) and 40.5% below its 100-day SMA, indicating significant short-term weakness. Shares have increased by 112.58% over the past 12 months and are currently positioned closer to their 52-week lows than highs.
The RSI is at 50.93, which is considered neutral territory, while the MACD is at 0.2738, below its signal line at 0.5506, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.
- Key Resistance: $52.50
- Key Support: $20.50
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $100.50. Recent analyst moves include:
- Canaccord Genuity: Buy (Lowers Target to $80.00) (Feb. 20)
- Baird: Outperform (Lowers Target to $82.00) (Feb. 20)
GRAL Price Action: Grail shares were down 2.27% at $49.07 during premarket trading on Monday.
Photo by Wirestock Creators via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The Wall Street "Stock Picking Myth" Continues to Fade: Only 13% Outperformed the Index in the Past Decade
According to the latest data from Morningstar, in the ten years up to the end of June 2026, only 13% of actively managed large-cap U.S. equity funds outperformed their benchmark indexes after fees, and even in the past year, this proportion was only 27%. Meanwhile, net inflows into passive ETFs this year are expected to surpass $1 trillion for the first time, and the asset size of passive funds is now nearly twice that of active funds.
Shiba Inu burn rate jumps 2,842% in 24 hours as Shibarium activity grows
Zcash trades near $490 as traders eye $500 resistance and $425 support
Dogecoin’s rare setup mirrors 2022 – Can DOGE repeat its 140% rally?
Crypto prices
More
